196 related articles for article (PubMed ID: 14604886)
21. Matrix metalloproteinase-2 promoter polymorphism is associated with breast cancer in a Mexican population.
Delgado-Enciso I; Cepeda-Lopez FR; Monrroy-Guizar EA; Bautista-Lam JR; Andrade-Soto M; Jonguitud-Olguin G; Rodriguez-Hernandez A; Anaya-Ventura A; Baltazar-Rodriguez LM; Orozco-Ruiz M; Soriano-Hernandez AD; Rodriguez-Sanchez IP; Lugo-Trampe A; Espinoza-Gomez F; Michel-Peregrina ML
Gynecol Obstet Invest; 2008; 65(1):68-72. PubMed ID: 17851253
[TBL] [Abstract][Full Text] [Related]
22. A study on the association of cytochrome-P450 1A1 polymorphism and breast cancer risk in north Indian women.
Singh V; Rastogi N; Sinha A; Kumar A; Mathur N; Singh MP
Breast Cancer Res Treat; 2007 Jan; 101(1):73-81. PubMed ID: 16807674
[TBL] [Abstract][Full Text] [Related]
23. Functional haplotypes in the promoter of matrix metalloproteinase-2 predict risk of the occurrence and metastasis of esophageal cancer.
Yu C; Zhou Y; Miao X; Xiong P; Tan W; Lin D
Cancer Res; 2004 Oct; 64(20):7622-8. PubMed ID: 15492291
[TBL] [Abstract][Full Text] [Related]
24. Polymorphisms of genes involved in extracellular matrix remodeling and abdominal aortic aneurysm.
Saracini C; Bolli P; Sticchi E; Pratesi G; Pulli R; Sofi F; Pratesi C; Gensini GF; Abbate R; Giusti B
J Vasc Surg; 2012 Jan; 55(1):171-179.e2. PubMed ID: 22094117
[TBL] [Abstract][Full Text] [Related]
25. Genetic polymorphisms of matrix metalloproteinases: susceptibility and prognostic implications for prostate cancer.
Dos Reis ST; Pontes J; Villanova FE; Borra PM; Antunes AA; Dall'oglio MF; Srougi M; Leite KR
J Urol; 2009 May; 181(5):2320-5. PubMed ID: 19303106
[TBL] [Abstract][Full Text] [Related]
26. Genetic polymorphisms of SULT1A1 and SULT1E1 and the risk and survival of breast cancer.
Choi JY; Lee KM; Park SK; Noh DY; Ahn SH; Chung HW; Han W; Kim JS; Shin SG; Jang IJ; Yoo KY; Hirvonen A; Kang D
Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1090-5. PubMed ID: 15894657
[TBL] [Abstract][Full Text] [Related]
27. No association between the polymorphisms in matrix metalloproteinase-1 and matrix metalloproteinase-3 promoter regions and colorectal cancer in Chinese.
Xu E; Lai M; Lŭ B; Xing X; Huang Q
Dis Colon Rectum; 2006 Sep; 49(9):1439-44. PubMed ID: 16937230
[TBL] [Abstract][Full Text] [Related]
28. MDR1 C3435T polymorphism in patients with breast cancer.
Turgut S; Yaren A; Kursunluoglu R; Turgut G
Arch Med Res; 2007 Jul; 38(5):539-44. PubMed ID: 17560460
[TBL] [Abstract][Full Text] [Related]
29. The matrix metalloproteinase-21 gene 572C/T polymorphism and the risk of breast cancer.
Shagisultanova EI; Novikova IA; Sidorenko YS; Marchenko GN; Strongin AY; Malkhosyan SR
Anticancer Res; 2004; 24(1):199-201. PubMed ID: 15015597
[TBL] [Abstract][Full Text] [Related]
30. Single nucleotide polymorphisms of tissue inhibitor of metalloproteinase genes in familial moyamoya disease.
Kang HS; Kim SK; Cho BK; Kim YY; Hwang YS; Wang KC
Neurosurgery; 2006 Jun; 58(6):1074-80; discussion 1074-80. PubMed ID: 16723886
[TBL] [Abstract][Full Text] [Related]
31. Population-based case-control study of VEGF gene polymorphisms and breast cancer risk among Chinese women.
Kataoka N; Cai Q; Wen W; Shu XO; Jin F; Gao YT; Zheng W
Cancer Epidemiol Biomarkers Prev; 2006 Jun; 15(6):1148-52. PubMed ID: 16775174
[TBL] [Abstract][Full Text] [Related]
32. Strong association of tissue inhibitor of metalloproteinase (TIMP)-2 and -3 promoter single nucleotide polymorphisms with risk of colorectal cancer in ethnic Kashmiri population - a case control study.
Banday MZ; Sameer AS
Biosci Rep; 2019 May; 39(5):. PubMed ID: 30988064
[No Abstract] [Full Text] [Related]
33. Clinicopathological significance of MMP-2 and TIMP-2 genotypes in gastric cancer.
Wu CY; Wu MS; Chen YJ; Chen CJ; Chen HP; Shun CT; Chen GH; Huang SP; Lin JT
Eur J Cancer; 2007 Mar; 43(4):799-808. PubMed ID: 17236757
[TBL] [Abstract][Full Text] [Related]
34. Joint effects of the CYP1A1 MspI, ERalpha PvuII, and ERalpha XbaI polymorphisms on the risk of breast cancer: results from a population-based case-control study in Shanghai, China.
Shen Y; Li DK; Wu J; Zhang Z; Gao E
Cancer Epidemiol Biomarkers Prev; 2006 Feb; 15(2):342-7. PubMed ID: 16492926
[TBL] [Abstract][Full Text] [Related]
35. ERCC2 genotypes and a corresponding haplotype are linked with breast cancer risk in a German population.
Justenhoven C; Hamann U; Pesch B; Harth V; Rabstein S; Baisch C; Vollmert C; Illig T; Ko YD; Brüning T; Brauch H
Cancer Epidemiol Biomarkers Prev; 2004 Dec; 13(12):2059-64. PubMed ID: 15598761
[TBL] [Abstract][Full Text] [Related]
36. In situ gene expression and localization of metalloproteinases MMP1, MMP2, MMP3, MMP9, and their inhibitors TIMP1 and TIMP2 in human renal cell carcinoma.
Bhuvarahamurthy V; Kristiansen GO; Johannsen M; Loening SA; Schnorr D; Jung K; Staack A
Oncol Rep; 2006 May; 15(5):1379-84. PubMed ID: 16596214
[TBL] [Abstract][Full Text] [Related]
37. Prognostic significance of the immunoexpression of matrix metalloproteinase MMP2 and its inhibitor TIMP2 in laryngeal cancer.
Danilewicz M; Sikorska B; Wagrowska-Danilewicz M
Med Sci Monit; 2003 Mar; 9(3):MT42-7. PubMed ID: 12640351
[TBL] [Abstract][Full Text] [Related]
38. Role of xenobiotic metabolizing gene polymorphisms in breast cancer susceptibility and treatment outcome.
Chacko P; Joseph T; Mathew BS; Rajan B; Pillai MR
Mutat Res; 2005 Mar; 581(1-2):153-63. PubMed ID: 15725614
[TBL] [Abstract][Full Text] [Related]
39. Matrix metalloproteinase-9 and matrix metalloproteinase-2 gene polymorphisms in multiple sclerosis.
Benesová Y; Vasků A; Stourac P; Hladíková M; Beránek M; Kadanka Z; Novotná H; Bednarík J
J Neuroimmunol; 2008 Dec; 205(1-2):105-9. PubMed ID: 18835646
[TBL] [Abstract][Full Text] [Related]
40. Polymorphisms of HER2 Ile655Val and cyclin D1 (CCND1) G870A are not associated with breast cancer risk but polymorphic allele of HER2 is associated with nodal metastases.
Naidu R; Yip CH; Taib NA
Neoplasma; 2008; 55(2):87-95. PubMed ID: 18237245
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
